Environmental

HLN’s R&D intensity of 2.8% of revenue suggests some resource commitment to product stewardship, but peer-relative evidence is insufficient to show a clear environmental edge.

The company’s capital structure is moderately leveraged, which can constrain funding flexibility for decarbonization or packaging-transition investments versus less levered peers.

No direct emissions, water, waste, or circularity disclosures were provided, limiting confidence that HLN outperforms peers on core environmental management.

Absent verified environmental metrics, HLN appears broadly in line with mid-pack consumer-health peers rather than structurally advantaged on environmental execution.

Social

HLN’s consumer-health profile makes product safety and quality central, and its high gross margin can support sustained investment in compliance and pharmacovigilance versus peers.

R&D spending at 2.8% of revenue indicates ongoing product development capacity, which can strengthen patient and consumer trust relative to lower-investing peers.

Stock-based compensation at 1.0% of revenue suggests moderate talent retention costs, but not a materially weaker social profile than comparable healthcare companies.

No controversy data were provided, so the assessment relies on disclosed operating metrics that suggest a solid but not leading social position.

Governance

Stock-based compensation of 1.0% of revenue indicates some alignment of management incentives, but peer-relative governance quality cannot be confirmed from the provided data.

Debt-to-equity of 0.50 and net debt-to-EBITDA of 2.6x imply manageable leverage, though not clearly stronger than conservatively financed peers.

The absence of board, audit, ownership, and controversy disclosures limits evidence of governance strength relative to peers.

Overall, HLN appears to have acceptable governance discipline, but the available metrics do not support a clear advantage over better-disclosed peers.

Overall Score

HLN’s ESG positioning appears broadly average to slightly above average versus peers, with the strongest support coming from social execution and limited evidence of a structural environmental or governance advantage.

Score Driver: Solid Social Profile Supported By Ongoing R&D Investment And No Disclosed Controversy Data.